FEATURED EDITORIAL
As understanding of immune-driven disease deepens, therapies that selectively correct dysregulated inflammation have the potential to reshape treatment paradigms.
- AI For NAM-Ready Drug Development: Turning Promise Into Trust
- From Cyclization To The Clinic: The Rising Era Of Cyclic Peptide Therapeutics
- Targeting Underlying Biology: Novel Combination Therapies For Chronic Disease
- Schrödinger's Equation Turns 100: How Quantum Chemistry Is Improving Drug Discovery
- Charting The Future Of Antimicrobial Resistance
- Annual Reflections And Predictions From The Editors' Roundtable
- The FXI Gamble: To Bleed Less... Or To Protect Less?
FEATURED APPLICATION CONTENT
-
Explore how leveraging expert CDMO partnerships can streamline the development process and enhance the efficacy of your bispecific antibody therapies.
-
Consider this alternative immunization approach — the PentaMice platform, a collection of five wildtype mouse strains bred in-house for increased MHC class II diversity — and how we're leveraging it for COVID-19 antibody discovery.
-
By forging strategic partnerships with comprehensive CDMOs, see how emerging biopharma firms can navigate through early-phase development and ensure a smooth transition to clinical advancement.
-
Explore how advanced single‑cell analysis links CAR localization, cell structure, and functional behavior, offering deeper insight into CAR T cell heterogeneity and performance.
-
Gain insight into automating DNA size selection that shows how optimized bead ratios and programmable handling improve fragment recovery, consistency, and throughput.
-
Gain insight into an automated high‑input workflow that streamlines long‑read whole‑genome library prep, supporting large DNA fragments while reducing reagent use.
-
A streamlined workflow reduces reagent use and hands‑on time while preserving long‑read sequencing quality. See how multiplexed offer an efficient option for scaling or mobilizing sequencing efforts.
-
Understanding covalent warhead kinetics is key to reducing safety risks early in discovery. Learn about a new approach to GSH‑based measurements that offers clearer predictors of toxicity.
-
See how a rapid digital PCR workflow enables reliable detection of trace RCL levels while maintaining strong performance in complex samples, which support more confident decisions in manufacturing.
-
Discover how mixed-mode chromatography enables high-yield purification of single-domain antibodies under mild conditions and why these approaches outperform traditional resins.
-
Scalable lentiviral vector production is moving beyond adherent systems. Learn how streamlined workflows enable linear scale-up in stirred-tank bioreactors for cost-effective gene therapy manufacturing.
-
Decoding immune cell interactions reveals critical insights for cancer therapy. Advanced imaging and spectral analysis enable precise identification of synapses, accelerating immuno-oncology research.
- Insights From The Non-Opioid Pain Therapeutics Summit: Human-Centric Translational Models And The Reawakening Of Pain Pipelines
- Schrödinger's Equation Turns 100: How Quantum Chemistry Is Improving Drug Discovery
- Annual Reflections And Predictions From The Editors' Roundtable
- The Unlikely Weapon Against Fentanyl: Your Immune System
- 2025's Top 5 Drug Discovery Highlights And How To Stay Ahead In 2026
FEATURED NEWS HEADLINES
- Akeso's IL-4Rα/ST2 Bispecific Antibody Cleared For Seven Phase II Studies In China Spanning Respiratory And Autoimmune Indications
- Precision BioSciences Receives U.S. FDA Clearance Of Investigational New Drug Application For First-In-Class PBGENE-DMD For Treatment Of Duchenne Muscular Dystrophy
- Lantern Pharma To Present At The 7th Glioblastoma Drug Development Summit In Boston On February 17-19, 2026
- AI-Powered R&D Acceleration: Insilico Medicine And CMS Announce Multiple Collaborations In Central Nervous System And Autoimmune Diseases
- Syngene Collaborates With Johns Hopkins University To Advance Early-Stage Drug Discovery
- U.S. Food And Drug Administration Accepts New Drug Application And Grants Priority Review For Takeda's Oveporexton (TAK-861) As A Potential First-In-Class Therapy For Narcolepsy Type 1
- NextPoint Therapeutics Announces Clinical Entry Of NPX372, A First-In-Class B7-H7–Targeted T Cell Engager To Treat Solid Tumors
- Iambic Announces Collaboration With Takeda To Advance AI-Driven Design Of Small Molecules
- Novartis Breaks Ground On New Global Biomedical Research Center In San Diego To Accelerate Drug Discovery
- IU Drug Discovery Initiative Helps Researchers Move Cancer Drugs From The Lab To Patients
ARCHIVED NEWSLETTER
- 02.10.26 -- Designing Drugs For Women: Closing The Therapeutic Gap
- 02.03.26 -- CROs In Early Drug Discovery, Part 3: Budgets, Timelines, And Avoiding Pitfalls
- 01.27.26 -- Schrödinger's Equation Turns 100: How Quantum Chemistry Is Improving Drug Discovery
- 01.20.26 -- CROs In Early Drug Discovery, Part 1: Choosing The Right Partner
- 01.13.26 -- Reflections And Predictions From The Editors' Roundtable